Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

Vos, Martine De, Louis, Edouard J., Jahnsen, Jørgen, Vandervoort, Jo G.P., Noman, Maja, Dewit, Olivier, DʼHaens, Geert R., Franchimont, Denis, Baert, Filip J., Torp, Roald A., Henriksen, Magne, Potvin, Philippe M.R., Van Hootegem, Philippe P., Hindryckx, Pieter M., Moreels, Tom G., Collard, Arnaud, Karlsen, Lars Normann, Kittang, Eirik, Lambrecht, Guy, Grimstad, Tore, Koch, Jonas, Lygren, Idar, Coche, Jean-Claude R.J., Mana, Fazia, Van Gossum, André, Belaiche, Jacques, Cool, Mike R., Fontaine, Fernand, Maisin, Jean-Marc G., Muls, Vinciane, Neuville, Bart, Staessen, Dirk A. J., Van Assche, Gert A., de Lange, Thomas, Solberg, Inger Camilla, Vander Cruyssen, Bert J.K., Vermeire, Severine A.R.A. · 2013 · Inflammatory Bowel Diseases

Abstract

BACKGROUND: This study examined whether fecal calprotectin can be used in daily practice as a marker to monitor patients with ulcerative colitis (UC) receiving infliximab maintenance therapy. METHODS: This prospective multicenter study enrolled adult patients with UC in clinical remission under infliximab maintenance therapy. Fecal calprotectin levels were measured every 4 weeks. Sigmoidoscopies were performed at inclusion and at study end. Relapse was defined as a clinical need for change in treatment or an endoscopic Mayo subscore of ≥2 at week 52. Sustained deep remission was defined as a partial Mayo score <3 at all points and an endoscopic Mayo score 0 at week 52. RESULTS: Full analysis was possible for 87 of 113 included patients with UC (77%). Of these patients, 30 (34.4%) were considered to be in sustained deep remission and 13 (14.9%) to have relapsed. Calprotectin levels in patients with sustained deep remission remained very low (median < 40 mg/kg at all time points). Patients who flared had significantly higher calprotectin levels (median > 300 mg/kg) already 3 months before the flare. Further receiver operator curve analysis suggested that a calprotectin level >300 mg/kg had a reasonable sensitivity (58.3%) and specificity (93.3%) to model flare. Two consecutive calprotectin measurements of >300 mg/kg with 1-month interval were identified as the best predictor of flare (61.5% sensitivity and 100% specificity). CONCLUSIONS: Fecal calprotectin can be used in daily practice to monitor patients with UC receiving infliximab maintenance therapy. Two consecutive measurements >300 mg/kg is more specific than a single measurement for predicting relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mib.0b013e31829b2a37

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 202

Metadata

Authors
Vos, M. D., Louis, E. J., Jahnsen, J., Vandervoort, J. G. P., Noman, M., Dewit, O., DʼHaens, G. R., Franchimont, D., Baert, F. J., Torp, R. A., Henriksen, M., Potvin, P. M. R., Van Hootegem, P. P., Hindryckx, P. M., Moreels, T. G., Collard, A., Karlsen, L. N., Kittang, E., Lambrecht, G., Grimstad, T., Koch, J., Lygren, I., Coche, J.-C. R. J., Mana, F., Van Gossum, A., Belaiche, J., Cool, M. R., Fontaine, F., Maisin, J.-M. G., Muls, V., Neuville, B., Staessen, D. A. J., Van Assche, G. A., de Lange, T., Solberg, I. C., Vander Cruyssen, B. J. K., & Vermeire, S. A. R. A.
Venue
Inflammatory Bowel Diseases
Published
2013-09
Volume
19
Issue
10
Pages
2111-2117
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2052776464
Cited by
202
References
1
FWCI
13.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.